Nosheen Reza, MD
Advanced Heart Failure and Transplant Cardiology · Philadelphia, PANPI 1467714279
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,767 of the $36,702 with a category attached, or 62.0%. It is spread thinly across 18 manufacturers, the largest accounting for just 19.3%. Reporting peaked in 2024 at $23,893 and has fallen 84.0% since, to $3,825 in 2025.
Across 50 payments — averaging $734.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Idorsia Pharmaceuticals US Inc$7K
- E.r. Squibb & Sons, L.L.C.$6K
- Novo Nordisk$6K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
- American Regent$4K
- Roche Diagnostics Corporation$3K
- plus $5K from 12 others
What the payments were for
- Consulting fees$22,76762%
- Speaking & faculty fees$11,08030%
- Travel & lodging$1,0123%
- Food & beverage$1,6635%
- Education$1810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Idorsia Pharmaceuticals US Inc | 1 | $7,080 |
| E.r. Squibb & Sons, L.L.C. | 10 | $6,253 |
| Novo Nordisk | 2 | $5,850 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $4,481 |
| American Regent | 1 | $4,320 |
| Roche Diagnostics Corporation | 1 | $3,390 |
| AstraZeneca | 2 | $1,733 |
| Roche Diagnostics International Ltd | 1 | $1,695 |
| Medtronic | 6 | $743 |
| Abbott | 6 | $302 |
| Astrazeneca UK Limited | 6 | $199 |
| Cvrx, Inc. | 1 | $173 |
| Edwards Lifesciences | 2 | $130 |
| Novartis | 1 | $124 |
| Merck | 1 | $108 |
| Endotronix, Inc. | 1 | $58 |
| Abiomed | 1 | $34 |
| Boston Scientific | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tryvio$7,080
- LifeVest$4,378
- INJECTAFER$4,320
- HeartWare HVAD$567
- Barostim Neo System$173
- HeartMate 3 Left Ventricular Dev$172
- ENTRESTO$124
- LEQVIO$124
- BREZTRI$122
How this compares
$36,702 in reported general payments places this provider in the 80th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
See all advanced heart failure and transplant cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 11 | $374 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Philadelphia
- Anjali VaidyaPhiladelphia$762K
- Jesus RamePhiladelphia$336K
- Ileana PinaPhiladelphia$284K
- Jeremy MazurekPhiladelphia$142K
- Lee GoldbergPhiladelphia$130K
- Anjali OwensPhiladelphia$109K
- Behnam BozorgniaPhiladelphia$107K
- Joyce WaldPhiladelphia$97K
- Paul MatherPhiladelphia$55K
- Hansie MathelierPhiladelphia$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.